O'Reilly Automotive Inc. Common Stock vs Sanofi SA — how do they compare? O'Reilly Automotive Inc. Common Stock trades at $86.45 (market cap $69.58B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 6.01% dividend while O'Reilly Automotive Inc. Common Stock pays none. Which is the better fit depends on your goals.
| ORLY | SNY | |
|---|---|---|
Market Cap | $69.58B | $95.18B |
Volume | 4,819,072 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $103.05 | $52.34 |
52-Week Low | $82.73 | $39.51 |
Enterprise Value | $78.90B | $114.48B |
Typical Hold Time | — | 94 Days |
Dividend Yield | — | 6.01% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
O'Reilly Automotive sells automotive aftermarket parts, tools, supplies, equipment, and accessories. It serves both professional service providers and do-it-yourself customers through its store network.
Read more on ORLY →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →